uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Go back to uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC| UNIQURE (NASDAQ: QURE) | Delayed: 41.81 -3.36 (7.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.17 | 52 Week High | $22.79 | |||
| Open | $45.99 | 52 Week Low | $6.63 | |||
| Day High | $46.10 | P/E | N/A | |||
| Day Low | $41.15 | EPS | $0.00 | |||
| Volume | 2,811,027 | |||||
